| Attributes | Values |
|---|
| rdf:type
| |
| description
| - videnskabelig artikel (da)
- article científic (ca)
- article scientific (oc)
- articol științific (ro)
- articolo scientifico (it)
- artigo científico (gl)
- artigo científico (pt)
- artigo científico (pt-br)
- artikull shkencor (sq)
- artikulong pang-agham (tl)
- artykuł naukowy (pl)
- bilimsel makale (tr)
- scienca artikolo (eo)
- teaduslik artikkel (et)
- tieteellinen artikkeli (fi)
- tudományos cikk (hu)
- vedecký článok (sk)
- vetenskaplig artikel (sv)
- vitenskapelig artikkel (nb)
- vitskapeleg artikkel (nn)
- vědecký článek (cs)
- wetenschappelijk artikel (nl)
- wissenschaftlicher Artikel (de)
- επιστημονικό άρθρο (el)
- научна статия (bg)
- научная статья (ru)
- научни чланак (sr)
- מאמר מדעי (he)
- სამეცნიერო სტატია (ka)
- บทความทางวิทยาศาสตร์ (th)
- artikel ilmiah (id)
- bài báo khoa học (vi)
- naučni članak (sr-el)
- мақолаи илмӣ (tg-cyrl)
- научни чланак (sr-ec)
- article scientifique (fr)
- 2008 nî lūn-bûn (nan)
- 2008年の論文 (ja)
- 2008年論文 (zh-hk)
- 2008年論文 (zh-tw)
- 2008年論文 (zh-hant)
- 2008年論文 (yue)
- 2008年論文 (zh-mo)
- 2008年论文 (zh)
- 2008年论文 (zh-cn)
- 2008年论文 (zh-sg)
- 2008年论文 (zh-hans)
- 2008年论文 (wuu)
- 2008年论文 (zh-my)
- 2008년 논문 (ko)
- artículo científico publicado en 2008 (es)
- artículu científicu espublizáu en 2008 (ast)
- наукова стаття, опублікована у вересні 2008 (uk)
- scientific article published on 22 September 2008 (en)
- scientific article published on 22 September 2008 (en-ca)
- scientific article published on 22 September 2008 (en-gb)
- مقالة علمية نشرت في 22 سبتمبر 2008 (ar)
- ২২ সেপ্টেম্বর ২০০৮-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ (bn)
|
| publication date
| |
| publication date
| |
| language of work or name
| |
| language of work or name
| |
| cites work
| |
| cites work
| - Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
- Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes.
- Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes.
- Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes
- Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.
- Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes
- Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study.
- Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.
- Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV
- A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies
- Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys
|
| author name string
| |
| author name string
| - Craig A Wilson
- Penny R Fleck
- Qais Mekki
- Alogliptin Study 010 Group
|
| rdfs:label
| - Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study (en)
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study (nl)
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study (ast)
|
| skos:prefLabel
| - Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study (en)
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study (nl)
|
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)